Literature DB >> 12432283

Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity.

Hong Zhou1, Michelle Ping Luo, Axel H Schönthal, Malcolm C Pike, Michael R Stallcup, Martina Blumenthal, Wenxin Zheng, Louis Dubeau.   

Abstract

We examined the effects of the 4 major female reproductive hormones, estradiol (E2), progesterone (P4), follicle stimulating hormone (FSH), and luteinizing hormone (LH) on thymidine incorporation in benign and malignant ovarian epithelial tumors cultured in vitro. Treatment of these tumors with E2, FSH and LH resulted in increased thymidine incorporation while treatment with P4 inhibited growth as well as thymidine incorporation. The inhibitory effect of progesterone could not be reproduced by treating the cells with ligands for other steroid hormone receptors known to interact with P4 such as the mineralocorticoid and glucocorticoid receptors. All cells lines expressed at least the PR-A isoform of the progesterone receptor. ORG2058, R5020, RU486, and ZK98299 acted as progesterone receptor agonists with regard to their effect on thymidine incorporation. P4 down-regulated cyclin Bl expression and cdkl activity and up-regulated the p21 and p27 proteins. Expression of a reporter gene downstream to an AP-1 responsive element in a plasmid construct transfected into ovarian epithelial tumor cells was induced by P4 and inhibited by RU486. We conclude that P4 inhibits cell cycle activity in ovarian epithelial tumors, in part via down-regulation of the cdkl/cyclin B complex. This inhibitory effect may have therapeutic utility against ovarian epithelial tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432283     DOI: 10.4161/cbt.86

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  11 in total

1.  Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer.

Authors:  Hao Hong; Hai-Yun Yen; Amy Brockmeyer; Ying Liu; Rajas Chodankar; Malcolm C Pike; Frank Z Stanczyk; Robert Maxson; Louis Dubeau
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

Review 2.  Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.

Authors:  Celeste Leigh Pearce; Karine Chung; Malcolm C Pike; Anna H Wu
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

3.  Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: the role of gonadotropins.

Authors:  Yael Chagit Tzuman; Stav Sapoznik; Dorit Granot; Nava Nevo; Michal Neeman
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

4.  Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.

Authors:  Louis Dubeau
Journal:  Transl Cancer Res       Date:  2015-02       Impact factor: 1.241

5.  Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.

Authors:  Caroline H Diep; Nathan J Charles; C Blake Gilks; Steve E Kalloger; Peter A Argenta; Carol A Lange
Journal:  Cell Cycle       Date:  2013-04-10       Impact factor: 4.534

6.  Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.

Authors:  Alicia A Goyeneche; Erin E Seidel; Carlos M Telleria
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

7.  Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.

Authors:  Ryuichi Murase; Tomoki Sumida; Akiko Ishikawa; Rumi Murase; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  Int J Otolaryngol       Date:  2011-11-21

Review 8.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

9.  BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions.

Authors:  Yiying Wang; Yue Wang; Li Wei; Shuhui Hong; Miaoqing Zhao; Xi Zhang; Wenxin Zheng
Journal:  J Ovarian Res       Date:  2017-03-07       Impact factor: 4.234

10.  Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.

Authors:  C L Pearce; A H Wu; S A Gayther; A E Bale; P A Beck; J Beesley; S Chanock; D W Cramer; R DiCioccio; R Edwards; Z S Fredericksen; M Garcia-Closas; E L Goode; A C Green; L C Hartmann; E Hogdall; S K Kjaer; J Lissowska; V McGuire; F Modugno; K Moysich; R B Ness; S J Ramus; H A Risch; T A Sellers; H Song; D O Stram; K L Terry; P M Webb; D C Whiteman; A S Whittemore; W Zheng; P D P Pharoah; G Chenevix-Trench; M C Pike; J Schildkraut; A Berchuck
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.